Genomic Health Oncotype DX AR-V7 Nucleus Detect
Genomic Health has launched its Oncotype DX AR-V7 Nucleus Detect Test, a liquid biopsy assay intended to predict treatment response in men with advanced prostate cancer. Developed initially by circulating tumor cell technology firm Epic Sciences, the new assay is the first of its kind to be commercially marketed. The test detects the presence of a splice variant of the androgen receptor protein in the nucleus of CTCs using Epic's detection and analysis platform.
The presence of AR-V7 has been shown in research studies to be predictive of whether men will respond to androgen receptor-signaling inhibitors like enzalutamide and abiraterone, or might be better served by chemotherapy.
Tempus xE Whole-Exome Tumor Sequencing
Personalized cancer technology company Tempus has introduced Tempus xE, a whole-exome sequencing panel that analyzes tumor DNA alongside a normal sample and a whole-RNA transcriptome. The new CLIA/CAP-validated assay gives researchers and clinicians a broad view of potential tumor mutations and treatment pathways, Tempus said.
Optra Health OptraGuru 'Digital Genetic Assistant'
Optra Health has introduced OptraGuru, an Amazon Alexa-compatible "digital genetic assistant" that allows consumers and healthcare professionals alike to verbally query genetic data. Meant to provide context to consumer genetic tests like those from Ancestry.com and 23andMe, OptraGuru puts the Alexa personal digital assistant on the front end of Optra Health's iPhronesis machine-learning platform to help patients, genetic counselors, and bioinformaticians make sense of genetic test results in a conversational manner.
For more new products and services, please visit the New Products page on our website.